Helix BioPharma Corp.

Helix BioPharma Corp.

January 05, 2005 16:51 ET

Helix Announces Election of New Board Member


NEWS RELEASE TRANSMITTED BY CCNMatthews

FOR: HELIX BIOPHARMA CORP.

TSX, FRANKFURT SYMBOL: HBP

JANUARY 5, 2005 - 16:51 ET

Helix Announces Election of New Board Member

AURORA, ONTARIO--(CCNMatthews - Jan. 5, 2005) - Helix BioPharma
(TSX:HBP)(FSE:HBP) is pleased to announce that today, at its Annual
General Meeting, Mr. Jack Kay, President and Chief Operating Officer of
Apotex Inc., was elected to its board of directors.

"We are very fortunate to have such an experienced pharmaceutical
executive join our board," said Jerry McElroy, Chairman of Helix
BioPharma. "Mr. Kay's wealth of knowledge will be of great assistance to
the Company as we move through our next development phase."

Mr. Kay has more than 40 years of experience in the pharmaceutical
industry, primarily in senior executive positions. In addition to
serving as the President and Chief Operating Officer of Apotex, Mr. Kay
is the director of two publicly traded pharmaceutical companies, as well
as the Chairman of the Board of the International Schizophrenic Society
and the Chairman of the Board of Directors of the Humber River Regional
Hospital in Toronto.

About Helix BioPharma

Helix BioPharma Corp. is a biopharmaceutical company specializing in the
field of cancer therapy. The Company is actively developing innovative
products for the prevention and treatment of cancer based on its
proprietary technologies. Helix's product development initiatives
include its Topical Interferon Alpha-2b, for the treatment of conditions
caused by the human papilloma virus, and its novel DOS47 new drug
candidate. Helix is listed on the TSX under the symbol "HBP".

The Toronto and Frankfurt Stock Exchanges have not reviewed and do not
accept responsibility for the adequacy or accuracy of the content of
this News Release. This News Release contains certain forward-looking
statements regarding, which can be identified by the use of
forward-looking terminology such as "will be", "developing", "move",
"initiative", or variations thereon or comparable terminology referring
to future events or results. Forward looking statements are statements
about the future and are inherently uncertain, and Helix's actual
results could differ materially from those anticipated in these
forward-looking statements as a result of numerous factors, including
without limitation, research & development risks, the risk of technical
obsolescence, the need for regulatory approval, which may not be
obtained in a timely matter or at all, the need for clinical trials, the
occurrence and success of which cannot be assured, intellectual property
risks, marketing/manufacturing and partnership/strategic alliance risks,
the effect of competition, uncertainty of the size and existence of a
market opportunity for Helix's products, Helix's need for additional
future capital, which may not be available in a timely manner or at all,
as well as a description of other risks and uncertainties affecting
Helix and its business, as contained in news releases and filings with
the Canadian Securities Regulatory Authorities, any of which could cause
actual results to vary materially from current results or Helix's
anticipated future results. Forward-looking statements are based on the
beliefs, opinions and expectations of Helix's management at the time
they are made, and Helix does not assume any obligation to update any
forward-looking statement should those beliefs, opinions or
expectations, or other circumstances change.

WKN: 918 846

-30-

Contact Information

  • FOR FURTHER INFORMATION PLEASE CONTACT:
    The Equicom Group Inc.
    Nick Hurst
    Investor Relations
    (416) 815-0700 ext. 226 or (800) 385-5451
    (416) 815-0080 (FAX)
    nhurst@equicomgroup.com